Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ICUI
ICUI logo

ICUI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
125.970
Open
124.750
VWAP
123.82
Vol
301.87K
Mkt Cap
3.08B
Low
122.250
Amount
37.38M
EV/EBITDA(TTM)
13.11
Total Shares
24.99M
EV
4.12B
EV/OCF(TTM)
24.58
P/S(TTM)
1.43
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume intravenous (IV) pumps and safety software, dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions. Its product offerings also include Consumables, Infusion Systems and Vital Care. Its consumables business unit includes infusion therapy, oncology, vascular access, and tracheostomy products. Its infusion systems offer a portfolio of infusion pumps, software, and professional services. Its vital care business unit includes hemodynamic monitoring, general anesthesia and respiratory, temperature management solutions and regional anesthesia/pain management products. Its infusion therapy products include infusion sets, extension sets, needle-free connectors, and disinfection caps.
Show More

Events Timeline

(ET)
2026-05-07
18:00:00
ICU Medical Reports Q1 Revenue of $530.23M
select
2026-02-19 (ET)
2026-02-19
16:30:00
Company Sees FY26 Adjusted EBITDA of $400M to $430M
select
2026-02-19
16:30:00
ICU Medical Reports Q4 Revenue of $540.7M
select

News

seekingalpha
9.5
05-08seekingalpha
ICU Medical Q1 2026 Earnings Call Insights
  • Slow Revenue Growth: ICU Medical reported revenue of $526 million for Q1 2026, reflecting a 1% organic growth but a 12% decline in reported figures, indicating weak market demand that could impact future investment confidence.
  • Margin Improvement: The adjusted gross margin for the first quarter was 41%, slightly exceeding expectations due to a favorable product mix in infusion businesses, which enhances the company's profitability in a competitive medical device market.
  • Free Cash Flow Performance: The company generated $28 million in free cash flow during the first quarter, despite recognizing $10 million in tariff expenses, demonstrating effective cash flow management that supports future debt reduction and capital returns.
  • Stable Market Outlook: Management reiterated that the full-year financial guidance remains applicable, estimating that a $10 increase in oil prices would result in an additional $3 million in annual expenses, highlighting the company's sensitivity to external economic factors and its strategic response.
Newsfilter
9.5
04-23Newsfilter
ICU Medical Announces Q1 2026 Earnings Release Schedule
  • Earnings Release Schedule: ICU Medical will release its Q1 2026 earnings on May 7, 2026, at 4:00 p.m. ET, reflecting the company's ongoing innovation and development in the medical products sector.
  • Conference Call Details: Following the earnings release, the company will hold a conference call at 4:30 p.m. ET on the same day, providing investors and analysts with an in-depth analysis of the financial results, enhancing transparency and communication.
  • Webcast Availability: The conference call will be accessible via webcast, allowing investors to easily access the information through the company's website, ensuring widespread dissemination and timely access to critical updates.
  • Company Background: ICU Medical is a global leader in infusion systems and high-value critical care products, committed to delivering quality and innovative medical solutions to clinical customers worldwide, further solidifying its market position.
PRnewswire
7.0
04-16PRnewswire
ICU Medical Under Investigation by Shareholders for Fiduciary Breach
  • Investigation Context: Purcell & Lefkowitz LLP is investigating ICU Medical, Inc. to determine if the company's directors breached their fiduciary duties in recent corporate actions, which could significantly impact shareholder rights.
  • Shareholder Rights Protection: The investigation focuses on safeguarding the interests of ICU Medical shareholders, and those interested in more information can contact the law firm to ensure their rights are upheld.
  • Commitment to Legal Services: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud and breaches of fiduciary duty, highlighting their expertise in protecting shareholder interests.
  • Free Legal Consultation: The firm offers free legal consultations, allowing shareholders to directly contact attorneys via phone or email to discuss case details and potential legal options.
PRnewswire
7.0
03-25PRnewswire
ICU Medical Under Investigation by Shareholders
  • Investigation Background: Purcell & Lefkowitz LLP is investigating ICU Medical, Inc. to determine if the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder rights.
  • Shareholder Rights Protection: The investigation focuses on safeguarding ICU Medical shareholders' interests, and shareholders seeking more information can contact the law firm through the provided details for free legal consultations.
  • Law Firm Overview: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide, specializing in cases of securities fraud, breaches of fiduciary duty, and other corporate misconduct, highlighting its expertise in shareholder rights protection.
  • Potential Impact: This investigation could negatively affect ICU Medical's corporate governance and shareholder trust, and if any wrongdoing by the board is found, it may lead to legal liabilities and damage to the company's reputation.
NASDAQ.COM
2.0
03-06NASDAQ.COM
ICU Medical Shares Enter Oversold Territory
  • Oversold Signal: ICU Medical Inc (Ticker: ICUI) saw its RSI drop to 29.96 during Friday's trading, indicating the stock has entered oversold territory, suggesting that the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
  • Price Fluctuation: ICUI shares hit a low of $129.18, with the current trading price at $132.00, showing significant volatility compared to the 52-week low of $107 and high of $160.29, reflecting drastic market sentiment changes.
  • Market Comparison: Compared to the S&P 500 ETF (SPY) RSI of 41.2, ICUI's oversold condition may attract bullish investors' attention, leading them to evaluate potential entry points for investment.
  • Investor Sentiment: Despite the current poor stock performance, the oversold signal could spark investor interest, especially if the market rebounds, potentially allowing ICUI's stock price to recover and present investment opportunities.
seekingalpha
9.5
02-20seekingalpha
ICU Medical Reports Q4 2025 Earnings Highlights
  • Revenue Growth: ICU Medical reported Q4 2025 revenue of $536 million, reflecting a 14% decline in reported terms but achieving 2% organic growth, with a full-year organic growth of 5%, indicating the company's stability and growth potential in the market.
  • Cost and Profit Analysis: The adjusted gross margin stood at 40.5%, aligning with prior guidance, while adjusted EBITDA was $98 million, a 7% decrease year-over-year primarily due to the deconsolidation of IV Solutions and tariffs, highlighting challenges in cost control.
  • Future Outlook: The company anticipates organic revenue growth in the low to mid-single-digit range for 2026, with an adjusted EBITDA target of $400 million to $430 million, reflecting management's confidence in future growth and market demand.
  • Strategic Integration Progress: Management emphasized the completion of several integration milestones, including the closure of the FDA warning letter, which is expected to provide more strategic options for the company and further drive innovation and operational synergies.
Wall Street analysts forecast ICUI stock price to rise
3 Analyst Rating
Wall Street analysts forecast ICUI stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
172.00
Averages
173.50
High
175.00
Current: 0.000
sliders
Low
172.00
Averages
173.50
High
175.00
KeyBanc
Overweight
downgrade
$180 -> $164
AI Analysis
2026-04-27
Reason
KeyBanc
Price Target
$180 -> $164
AI Analysis
2026-04-27
downgrade
Overweight
Reason
KeyBanc lowered the firm's price target on ICU Medical to $164 from $180 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes underlying MedTech trends continue to track well ahead of subdued market performance, which it thinks is mostly attributable to various macro items weighing on investor sentiment.
Piper Sandler
Jason Bednar
Overweight
downgrade
$178 -> $163
2026-04-17
Reason
Piper Sandler
Jason Bednar
Price Target
$178 -> $163
2026-04-17
downgrade
Overweight
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on ICU Medical to $163 from $178 and keeps an Overweight rating on the shares. In addition to updated Fx assumptions, the firm is slightly adjusting Q1 organic growth estimates for Consumables and Vital Care to align more with consensus.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ICUI
Unlock Now

Valuation Metrics

The current forward P/E ratio for ICU Medical Inc (ICUI.O) is 15.48, compared to its 5-year average forward P/E of -21.39. For a more detailed relative valuation and DCF analysis to assess ICU Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-21.39
Current PE
15.48
Overvalued PE
228.23
Undervalued PE
-271.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
12.99
Current EV/EBITDA
12.37
Overvalued EV/EBITDA
14.73
Undervalued EV/EBITDA
11.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.77
Current PS
1.37
Overvalued PS
2.38
Undervalued PS
1.15

Financials

AI Analysis
Annual
Quarterly

Whales Holding ICUI

O
Oberweis Asset Management, Inc.
Holding
ICUI
+53.35%
3M Return
S
Segall Bryant & Hamill, LLC
Holding
ICUI
+10.12%
3M Return
F
Fuller & Thaler Asset Management, Inc.
Holding
ICUI
+7.54%
3M Return
R
River Road Asset Management, LLC
Holding
ICUI
-1.27%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is ICU Medical Inc (ICUI) stock price today?

The current price of ICUI is 123.23 USD — it has decreased -1.16

What is ICU Medical Inc (ICUI)'s business?

ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume intravenous (IV) pumps and safety software, dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions. Its product offerings also include Consumables, Infusion Systems and Vital Care. Its consumables business unit includes infusion therapy, oncology, vascular access, and tracheostomy products. Its infusion systems offer a portfolio of infusion pumps, software, and professional services. Its vital care business unit includes hemodynamic monitoring, general anesthesia and respiratory, temperature management solutions and regional anesthesia/pain management products. Its infusion therapy products include infusion sets, extension sets, needle-free connectors, and disinfection caps.

What is the price predicton of ICUI Stock?

Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is173.50 USD with a low forecast of 172.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ICU Medical Inc (ICUI)'s revenue for the last quarter?

ICU Medical Inc revenue for the last quarter amounts to 530.23M USD, decreased -12.32

What is ICU Medical Inc (ICUI)'s earnings per share (EPS) for the last quarter?

ICU Medical Inc. EPS for the last quarter amounts to 1.20 USD, decreased -290.48

How many employees does ICU Medical Inc (ICUI). have?

ICU Medical Inc (ICUI) has 13000 emplpoyees as of May 13 2026.

What is ICU Medical Inc (ICUI) market cap?

Today ICUI has the market capitalization of 3.08B USD.